Related Experiment Video

Updated: Jul 6, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism

Liping Qiao1, Chenhui Zou, Deneys R van der Westhuyzen

  • 1Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA.

Diabetes
|April 1, 2008
PubMed
Abstract

Insights

Adiponectin lowers plasma triglyceride levels by enhancing skeletal muscle lipoprotein lipase (LPL) and VLDL receptor (VLDLr) expression, thereby increasing VLDL-triglyceride (VLDL-TG) breakdown.

Area of Science:

  • Metabolic research
  • Endocrinology
  • Lipid metabolism

Background:

  • Adiponectin, an adipocyte-derived hormone, is crucial for glucose and lipid metabolism.
  • Understanding adiponectin's role in very-low-density lipoprotein triglyceride (VLDL-TG) metabolism is essential.

Purpose of the Study:

  • To investigate the effects of adiponectin on VLDL-TG metabolism.
  • To elucidate the underlying mechanisms of adiponectin's action on VLDL-TG.

Main Methods:

  • A mouse model with elevated adiponectin was generated using adenoviruses.
  • HepG2 and C2C12 cells were treated with recombinant human adiponectin.

Main Results:

  • Elevated plasma adiponectin significantly decreased fasting plasma TG levels and VLDL subclasses in mice.
  • Adiponectin increased postheparin plasma lipoprotein lipase (LPL) activity and skeletal muscle LPL and VLDL receptor (VLDLr) expression.
  • Hepatic VLDL-TG secretion rates were not altered, indicating a post-transcriptional mechanism.

Conclusions:

  • Adiponectin reduces plasma TG levels by upregulating skeletal muscle LPL and VLDLr.
  • This leads to increased VLDL-TG catabolism, offering a potential therapeutic target for dyslipidemia.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipid Catabolism01:25

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...